While no dengue vaccine has yet been approved for general use, several candidates are in clinical development. Data from the clinical trials can be used in mathematical models to estimate the benefits and risks and of different vaccination strategies. A new study suggests that even a moderately efficient dengue vaccine -- if it induces long-lasting immunity -- can substantially reduce disease burden.
While no dengue vaccine has yet been approved for general use, several candidates are in clinical development. Data from the clinical trials can be used in mathematical models to estimate the benefits and risks and of different vaccination strategies. A new study suggests that even a moderately efficient dengue vaccine -- if it induces long-lasting immunity -- can substantially reduce disease burden.
Share this Article
Recommended